The underlying mechanism is probably inadequate cleavage of UL–VWF, leading to enhanced platelet–vessel wall interactions and subsequently to thrombotic microangiopathy, associated with thrombocytopenia, nonimmune hemolysis and end-organ damage [94]. Here, VWF is linked to Genetic thrombotic microangiopathy.